• Fasudil (HA-1077) HCl: ROCK Inhibitor Workflows

  2026-09-24

  Fasudil (HA-1077) HCl offers a practical way to perturb ROCK signaling while measuring proliferation, motility, and apoptosis in the same experimental framework. This guide separates established product data from suggested pilot conditions and explains how to use cataract-related Hippo research as an assay-design reference—not as evidence that Fasudil protects the lens.

• 25-Hydroxycholesterol Reprograms Tumor Macrophages via AMPK

  2026-09-24

  Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic signal that accumulates in tumor-associated macrophage lysosomes and activates AMPKα through a GPR155–mTORC1 pathway. Their findings connect AMPK activity to STAT6-dependent ARG1 expression and suggest that targeting CH25H can strengthen antitumor T-cell responses, including alongside anti-PD-1 therapy.

• PP2A, Autophagy, and Candida Biofilm Drug Resistance

  2026-09-23

  The study links the PP2A catalytic-subunit gene PPH21 to autophagy, biofilm formation, and antifungal resistance in Candida albicans. Its mutant and rapamycin experiments support a model in which PP2A-dependent regulation of Atg13 and Atg1 helps autophagy promote biofilm-associated drug tolerance, while the mouse oral-infection findings provide an initial in vivo test of that relationship.

• AT-406: A Model-Selection Framework for IAP Research

  2026-09-23

  AT-406 (SM-406) is an orally bioavailable IAP antagonist for dissecting apoptosis pathway activation in cancer cells. This article presents a model-selection and assay-interpretation framework, using an in vivo CRISPR study of Toxoplasma virulence as a disciplined example of how context, rescue experiments, and phenotype timing strengthen cancer research conclusions.

• Dhcr7 Knockout Grass Carp and GCRV Resistance

  2026-09-22

  A 2026 Aquaculture Reports study used CRISPR/Cas9 to disrupt dhcr7 in grass carp and provide in vivo evidence that this cholesterol-biosynthesis gene influences resistance to GCRV-II. The edited fish showed improved survival and antiviral responses without detectable growth or muscle-morphology penalties, supporting Dhcr7 as a candidate target for disease-resistant aquaculture breeding.

• Cefiderocol Activity in Resistant European Non-Fermenters

  2026-09-22

  This 2024 European surveillance study directly compared cefiderocol with β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa and Acinetobacter spp., including meropenem-resistant isolates. Cefiderocol showed consistently high in vitro susceptibility, while genomic analysis connected cefiderocol resistance to siderophore-uptake pathway changes and, in Acinetobacter, acquired β-lactamase determinants.

• Naftifine HCl: Designing Mechanism-First Assays

  2026-09-21

  Naftifine HCl is an allylamine antifungal agent whose defined sterol-biosynthesis target supports rigorous, mechanism-first assay design. This article connects fungal target engagement with practical lessons from WNT5a/GSK3/β-catenin research while clearly separating validated pharmacology from exploratory cross-domain hypotheses.

• Protease Inhibitor Cocktail for cGAS Assays

  2026-09-21

  Protect fragile cGAS-pathway proteins during extraction, Western blotting, co-immunoprecipitation, and kinase analysis with an EDTA-free formulation. The 200X DMSO stock preserves compatibility with divalent-cation-dependent assays while broad inhibitor coverage helps limit ex vivo protein degradation.

• Bromodomain Inhibitor, (+)-JQ1: Bench Workflows

  2026-09-20

  Build more informative BET experiments with (+)-JQ1 by separating growth arrest from true cell killing, then extend the workflow to BRD4, inflammatory signaling, and BRDT research. Practical formulation, timing, and troubleshooting guidance helps turn a dose-response experiment into a mechanistically interpretable assay.

• REV1–DHX36 Control of G-Quadruplex Tolerance

  2026-09-19

  A 2026 Nucleic Acids Research study identifies a direct REV1–DHX36 interaction that coordinates G-quadruplex unwinding, replication-fork progression, and suppression of single-stranded DNA gaps. The findings provide a mechanistic framework for understanding how G4 stabilization activates genome-damage signaling and creates vulnerabilities relevant to cancer research.

• Midecamycin: Practical Antibacterial Assay Workflows

  2026-09-18

  Midecamycin is an acetoxy-substituted macrolide antibiotic for structured in vitro profiling of susceptible Gram-positive organisms, with built-in value as a resistance and assay-control compound. This guide translates published MIC methods into practical stock preparation, screening, MBC confirmation, glycosylation studies, and troubleshooting workflows.

• Thymoquinone Workflows for Cardiotoxicity

  2026-09-18

  Build mechanism-resolved doxorubicin cardiotoxicity studies with Thymoquinone, linking cardiac function to oxidative stress, ferroptosis, and mitochondrial injury. This workflow separates literature-matched mouse dosing from practical formulation, cell-assay optimization, and troubleshooting decisions.

• Psoralen, Isopsoralen, and ERK1/2 Cholestasis

  2026-09-17

  A 2024 Chemical Research in Toxicology study identified ERK1/2 activation as a mechanistic link between the phytoestrogens psoralen and isopsoralen and cholestatic liver injury in zebrafish larvae. By combining estrogen-response measurements, bile-acid gene profiling, phosphorylation analysis, and pharmacological rescue, the work positions ERK1/2 as a testable target in phytoestrogen-associated cholestasis research.

• Biotin-HPDP: Mapping Cysteine Signaling

  2026-09-17

  Biotin-HPDP enables reversible thiol-specific protein labeling for affinity capture, redox analysis, and modification studies. This guide explains how to interpret Biotin-HPDP data in the context of GSDMD palmitoylation and functional pyroptosis assays.

• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-09-16

  The reference study identifies CD44 as a functional metabolic dependency in IDH-mutant leukemia, linking pentose phosphate pathway activity and NADPH production to sustained R-2HG synthesis. Its isogenic CRISPR design supports a mechanistic rationale for combining mutant-IDH inhibition with CD44 blockade in acute myeloid leukemia research, while also highlighting important limitations for clinical translation.

8203 records 1/547 page Next 12345 下5页 Last page